Completed PHASE1 INTERVENTIONAL 3-arm NCT02307461

Bioequivalence of Duvelisib and Food Effect on Pharmacokinetics of IPI-145

A Phase 1, Open-label, 2-Part Study to Evaluate the Bioequivalence of the Duvelisib Marker-Image Formulation to the Duvelisib Clinical-Trial Formulation and to Assess the Effect of Food on the Pharmacokinetics of IP Duvelisib in Healthy Adult Subjects

Sponsor: SecuraBio

Conditions Healthy

Interventions IPI-145 IPI-145 (duvelisib)

Updated 8 times since 2017 Last updated: Mar 15, 2021 Started: Nov 30, 2014 Primary completion: Aug 31, 2015 Completion: Sep 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02307461, this PHASE1 trial focuses on Healthy and remains completed. Sponsored by SecuraBio, it has been updated 8 times since 2014, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Apr 2021 — Jul 2024 [monthly]

Completed PHASE1
Jan 2021 — Apr 2021 [monthly]

Completed PHASE1
Nov 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 3 earlier versions

Jun 2018 — Nov 2018 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Nov 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

SecuraBio

Data source: SecuraBio

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Lenexa, United States